Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. - Wikidata - wikimedia - TriplyDB

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

http://www.wikidata.org/entity/Q35114490

about

Diet and Alzheimer’s disease risk factors or prevention: the current evidence Biological markers of amyloid beta-related mechanisms in Alzheimer's disease The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Cerebrospinal fluid and blood biomarkers in Alzheimer's disease Dementia revealed: novel chromosome 6 locus for late-onset Alzheimer disease provides genetic evidence for folate-pathway abnormalities 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.What the study of persons at risk for familial Alzheimer's disease can tell us about the earliest stages of the disorder: a review.The role of biomarkers in clinical trials for Alzheimer disease The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer's Disease.Biomarker identification in neurologic diseases: improving diagnostics and therapeutics.Total and phosphorylated tau protein as biological markers of Alzheimer's disease.Altered proteolysis in fibroblasts of Alzheimer patients with predictive implications for subjects at risk of disease Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications.Mapping Alzheimer's disease progression in 1309 MRI scans: power estimates for different inter-scan intervals.Diagnosis and biomarkers of predementia in Alzheimer's disease.Olfactory impairment in presymptomatic Alzheimer's disease.Cerebrospinal fluid abnormalities and rate of decline in everyday function across the dementia spectrum: normal aging, mild cognitive impairment, and Alzheimer disease.The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.Sex and age differences in atrophic rates: an ADNI study with n=1368 MRI scans Biological markers and Alzheimer disease: a canadian perspective Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry Structural MRI biomarkers for preclinical and mild Alzheimer's disease.A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study.Mediterranean diet, Alzheimer disease, and vascular mediation Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.The application of functional genomics to Alzheimer's disease.Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.CSF tau and β-amyloid as biomarkers for mild cognitive impairment.Biological markers for early detection and pharmacological treatment of Alzheimer's disease.Metabolic interaction between ApoE genotype and onset age in Alzheimer's disease: implications for brain reserve.Using biomarkers to improve detection of Alzheimer's disease.Looking backward to move forward: early detection of neurodegenerative disorders.Association of C-reactive protein with cognitive impairment.Diagnostic Utility of CSF Tau and Aβ(42) in Dementia: A Meta-Analysis.Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics Variations in the FRA10AC1 Fragile Site and 15q21 Are Associated with Cerebrospinal Fluid Aβ1-42 Level.

P2860

Q22241476-6A403CEE-ECF7-4A90-966F-544BBD0F0724 Q24622136-EABA3FF4-D1AC-4733-966A-D81F0D2B65F2 Q26849795-BBFC4D44-8E5F-4E08-80D5-8DB48D443156 Q27006831-B6E20182-6D9E-437B-A848-F6A8F66BAAD9 Q27023758-AA1F809E-2E83-4591-873E-D5D71ED566E1 Q28943531-C1E6C841-8F6F-4805-995D-F050379F99C9 Q30971403-E4EB4C6D-D6DC-43AB-9B8F-C2F4C6C36A71 Q31020589-C93CB8F3-6C87-47DF-BE2C-CB8EE6A04F0A Q31032781-566B3967-F35C-4B41-9CB9-230895D82CFE Q31048037-A4E2857C-77F5-4271-A65E-36E807C7B44C Q33202814-1CEC96EA-F699-46A9-B4FD-EC7BF67F561B Q33624674-74192EC7-7373-4C45-B632-8CC803A50B51 Q33736357-D3272B65-88BB-4F8B-95D3-156AEE8D4C17 Q33736582-35F1A9CB-A5D0-419D-9F79-3777D0D00561 Q33759240-AC5C2152-1C5E-419F-A895-06101D90B727 Q33777509-AA83C468-B919-460B-821E-9D4C819E2FC6 Q33802937-B54FA7FA-C9A3-4EC8-8C44-A8B0BBDDC8CF Q33924646-62BB5276-647A-40A6-B6E8-BEEA0BB3C474 Q34065449-BE8A657B-388A-4294-9428-FA21C841AEB3 Q34081087-DD9CAEC6-F3F7-4149-90D0-CAFC08B863CE Q34089784-91018BB9-6351-4B35-84B9-5DA0298A286A Q34157882-A73B2F57-D309-44D4-9CC0-65A5D49B42CA Q34180987-B890F642-958E-4B8F-A142-F139598291AF Q34341870-53FFA6E9-E6D4-4F8C-AB0E-7BAE04B4CAD4 Q34510165-76DB9EAC-E71F-499F-B3E4-1B35B769931A Q34633220-75C7D6BB-40C7-473E-ADCB-0C71ED02CC5E Q34648414-E47C9B94-634E-4AA2-B92C-4754AF250B38 Q35029086-3F830200-570E-4EB8-AA2D-D1CEBD5E7162 Q35166684-4F226A79-FD7E-4734-984D-DF14586F7B45 Q35207554-A99836A8-352A-4E80-9F90-97C4BEE63FFD Q35218413-8E9A2C14-F93A-4A11-8E3D-308DDACC81D1 Q35236838-410D3BB2-AA84-46C3-8E1C-B31ABAF24DC1 Q35237100-9DC78982-C4A1-481E-9367-71C2F6B74E0C Q35483725-2D7934E4-EE3D-4DC2-BF5F-17B22F55993D Q35533115-505ABB12-C2FE-465B-BAD8-873837FF9711 Q35573431-F3B54452-FBE6-4033-BAAE-91509C97EAE2 Q35591752-E00817B2-2640-4A14-A757-04438447803C Q35606785-EE83C342-94B0-4C8D-AB0D-D0DE03DC79B1 Q35649302-57064FF7-0AEA-4C40-AAFB-D62EF4C0052F Q35740031-DCAF5AE7-96BB-41A2-B7E8-6242E3BAA79A

P2860

Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

http://www.wikidata.org/entity/Q35114490

description

2003 nî lūn-bûn

@nan

2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Biological markers for therape ...... maging in Alzheimer's disease.

@ast

Biological markers for therape ...... maging in Alzheimer's disease.

@en

type

label

Biological markers for therape ...... maging in Alzheimer's disease.

@ast

Biological markers for therape ...... maging in Alzheimer's disease.

@en

prefLabel

Biological markers for therape ...... maging in Alzheimer's disease.

@ast

Biological markers for therape ...... maging in Alzheimer's disease.

@en

P1433

Q35114490-FE901DF9-8242-4276-95A2-925B4D595FE5

P1476

Q35114490-D0007D69-5799-4E68-AC40-4087AC2F1F9F

P2093

Q35114490-065FCE79-CEC3-49AF-91DD-A745D440E320

Q35114490-4DAADE94-D544-409E-B726-7E9C6011B178

Q35114490-A1F4933E-0970-4C75-8752-21D97370B6D6

Q35114490-A32EA35E-D3EF-4D32-8EF3-2C1DD3D532FC

Q35114490-B0412BD0-2CC9-4916-8206-A06C9084A7F3

Q35114490-C1FB4339-E5EE-4A76-A4B7-1BB44A9A5EFB

Q35114490-C71F07A0-29C1-4C57-987F-B2D7C7C25B72

P304

Q35114490-C9F8FFB6-62EF-44F3-9060-B055B9C8C3B6

P31

Q35114490-AF6DA27A-1299-4743-8376-36AA5FCA85B5

P356

Q35114490-2272050C-4C14-4460-BDC8-04EDFF67A05E

P433

Q35114490-84D8CF9F-2713-4F6E-8D46-E5C61A8E47EF

P478

Q35114490-B5FA579A-CCEA-45BC-ABF5-F2956563899C

P50

Q35114490-554EE2D9-197A-4BDF-8BD5-59511F30C2F6

Q35114490-AD55F82A-B6D1-4323-884C-97B4E473DEF0

Q35114490-BAEE8A85-8DA9-40E5-9CE5-2A66443553BF

P577

Q35114490-CE0AB150-B687-4A61-ABB7-6EAEB34D3592

P698

Q35114490-C1CEA34A-7A96-4364-A207-FFB594C53659

P921

Q35114490-626C6848-0935-4B9B-99EE-D416F09F3687

Q35114490-6E11591F-DAF1-48BF-8801-45C1B8CEAA4B

Q35114490-8CCE3BD9-4970-4E98-A31F-FB1A7EE888E8

P356

S0197-4580(03)00002-2

P1433

Neurobiology of Aging

P1476

Biological markers for therape ...... maging in Alzheimer's disease.

@en

P2093

Douglas Galasko

http://www.w3.org/2001/XMLSchema#string

Eric Siemers

http://www.w3.org/2001/XMLSchema#string

Joseph Rogers

http://www.w3.org/2001/XMLSchema#string

Mony J de Leon

http://www.w3.org/2001/XMLSchema#string

National Institute on Aging Biological Markers Working Group

http://www.w3.org/2001/XMLSchema#string

Pankaj D Mehta

http://www.w3.org/2001/XMLSchema#string

Richard A Frank

http://www.w3.org/2001/XMLSchema#string

P304

521-536

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0197-4580(03)00002-2

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

John Anthony Hardy

John Q. Trojanowski

P577

2003-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12714109

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

Alzheimer's Disease Neuroimaging Initiative